Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -146.40M | -129.14M | -73.91M | -50.16M | 158.52M |
| Total Depreciation and Amortization | 30.89M | 28.75M | 28.06M | 26.85M | 24.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.40M | 66.23M | 67.65M | 64.46M | 64.31M |
| Change in Net Operating Assets | 13.23M | 40.81M | -141.84M | 91.94M | 29.83M |
| Cash from Operations | -43.88M | 6.65M | -120.03M | 133.08M | 277.36M |
| Capital Expenditure | -76.95M | -74.85M | -67.03M | -71.15M | -70.66M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -144.16M | -139.00M | -416.03M | -404.71M | -281.97M |
| Cash from Investing | -221.11M | -213.85M | -483.06M | -475.86M | -352.63M |
| Total Debt Issued | 11.59M | 7.99M | 1.22M | 1.30M | 2.76M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.23M | -1.05M | -927.00K | -259.00K | -4.38M |
| Cash from Financing | 10.36M | 6.94M | 291.00K | 1.05M | -1.63M |
| Foreign Exchange rate Adjustments | 589.00K | -115.00K | -7.60M | -9.61M | -9.60M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -254.04M | -200.38M | -610.40M | -351.35M | -86.49M |